Buccal Drug Delivery Systems

Buccal Drug Delivery Systems Market Outlook

The global Buccal Drug Delivery Systems market is projected to reach approximately USD 9.8 billion by 2035, growing at a CAGR of around 10.5% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing demand for non-invasive drug delivery methods that enhance patient compliance and convenience. Additionally, innovative formulations and advancements in drug delivery technologies are driving this market forward. The growing prevalence of chronic diseases, coupled with an aging population, is further expected to fuel the need for effective pain management and hormone replacement therapies, thereby propelling the market for buccal drug delivery systems. Furthermore, increased awareness about the benefits of buccal administration over traditional routes is encouraging research and development activities in this sector.

Growth Factor of the Market

The Buccal Drug Delivery Systems market is witnessing substantial growth primarily due to the rising need for rapid drug absorption and the ability to bypass the gastrointestinal tract, which can degrade or alter the efficacy of many medications. The preference for buccal delivery systems is growing among consumers and healthcare providers alike due to their ease of use and higher bioavailability compared to other routes. Moreover, the expansion of the pharmaceutical industry, along with ongoing research to develop more effective formulations, provides a significant boost to the market. Additionally, the rising trend towards personalized medicine and tailored therapies is expected to open new avenues for buccal drug delivery systems, catering to specific patient needs. The integration of advanced technologies in formulation development is also anticipated to enhance the efficiency and effectiveness of drug delivery systems, further driving market growth.

Key Highlights of the Market

• The global market is projected to reach USD 9.8 billion by 2035, growing at a notable CAGR of 10.5%.
• Increased patient compliance due to non-invasive and convenient delivery methods.
• Rising prevalence of chronic diseases, notably in pain management and hormone replacement.
• Advancements in drug formulation technologies enhancing bioavailability.
• Growing awareness and acceptance of buccal drug delivery systems among healthcare professionals and patients.

By Product Type

Mucoadhesive Tablets:

Mucoadhesive tablets are one of the most commonly used forms of buccal drug delivery systems due to their ability to adhere to the mucosal surfaces of the oral cavity, allowing for prolonged drug release and absorption. These tablets are designed to dissolve slowly, which maximizes the time the active pharmaceutical ingredient (API) remains in contact with the mucosal membrane, enhancing bioavailability. The growing demand for pain management medications and hormone replacement therapies is driving the market for mucoadhesive tablets, as they provide a convenient and effective means of administration. Additionally, their ease of manufacture and formulation flexibility makes them a preferred choice for many pharmaceutical companies. The increasing focus on patient-centric drug delivery systems is also contributing to the growth of this segment.

Buccal Patches:

Buccal patches have emerged as a novel method for drug delivery, utilizing a thin film that adheres to the buccal mucosa. These patches are designed to release the active ingredient over a specified duration, providing a controlled and steady release of medication into the bloodstream. The growing incidence of chronic conditions that require continuous medication, such as diabetes and hypertension, is driving the adoption of buccal patches. Their ability to bypass first-pass metabolism and improve bioavailability makes them an attractive option for both patients and healthcare providers. Furthermore, ongoing research into the development of biodegradable and mucoadhesive polymers for buccal patches is expected to enhance their efficacy and patient compliance, further promoting their market growth.

Lozenges:

Lozenges represent another significant product type in the buccal drug delivery systems market. These solid formulations are designed to dissolve in the mouth, allowing for the gradual release of the active ingredient. Lozenges are particularly popular for treating conditions such as sore throats, coughs, and oral discomfort, primarily due to their ease of use and palatable nature. The growing demand for over-the-counter medications and self-care products is boosting the lozenges segment. Additionally, the ability to incorporate various flavors and sweeteners enhances their appeal among consumers, particularly in pediatric applications. As more consumers seek non-invasive and convenient healthcare options, the popularity of lozenges is expected to continue rising.

Gels:

Gels used in buccal drug delivery systems offer an innovative approach to drug administration, providing a semi-solid form that can be easily applied to the oral mucosa. These formulations allow for quick absorption of medications, making them ideal for rapid relief in situations such as pain or discomfort. The versatility of gels enables the incorporation of various active ingredients, such as analgesics and anti-inflammatory drugs, catering to a diverse range of therapeutic applications. Moreover, the non-invasive nature of gels makes them appealing to patients who may be reluctant to use injections or traditional oral medications. Continuous advancements in gel formulation technology are expected to enhance their effectiveness and patient compliance, driving the growth of this segment.

Films:

Buccal films are thin, flexible sheets that dissolve quickly when placed in the oral cavity, delivering the active ingredient directly into the bloodstream. This method offers numerous advantages, including fast onset of action and improved bioavailability, making buccal films particularly suitable for acute conditions that require immediate relief, such as pain or nausea. The growing popularity of films is largely driven by their convenience and discreet nature, appealing to a wide demographic of patients. Additionally, advancements in polymer technology are facilitating the development of films with enhanced properties, such as extended release profiles and improved taste masking. As the demand for innovative drug delivery methods increases, buccal films are anticipated to see significant growth in the coming years.

By Application

Pain Management:

The application of buccal drug delivery systems in pain management is rapidly growing, primarily due to their ability to provide fast relief for various types of pain, including acute and chronic conditions. Buccal formulations allow for quick absorption of analgesics, bypassing the gastrointestinal tract and avoiding first-pass metabolism, which can diminish drug efficacy. This method is especially beneficial for patients who may have difficulties swallowing pills or require rapid intervention for pain relief. The increasing prevalence of chronic pain disorders, such as arthritis and neuropathic pain, is driving the demand for effective and convenient pain management solutions. Furthermore, ongoing research into the development of new analgesics specifically designed for buccal delivery is expected to enhance treatment options and drive market growth.

Hormone Replacement:

Buccal drug delivery systems are gaining traction in the field of hormone replacement therapy, providing a viable alternative to traditional oral and injectable methods. The ability to deliver hormones directly into the bloodstream via the buccal mucosa allows for improved bioavailability and a more consistent pharmacokinetic profile. This is particularly important for hormones such as testosterone and estrogen, which require precise dosing for optimal therapeutic effects. The increasing awareness of the benefits of hormone replacement therapy, coupled with the growing aging population seeking relief from menopausal symptoms and other hormonal imbalances, is propelling the demand for buccal delivery systems. As research continues to explore new applications in hormone therapy, the market is expected to expand further.

Smoking Cessation:

Buccal drug delivery systems play a crucial role in smoking cessation programs, as they provide an effective means of delivering nicotine replacement therapies. Products such as buccal patches and lozenges offer smokers a method to manage cravings and withdrawal symptoms, facilitating the transition away from tobacco use. The convenience and ease of use of these systems are major factors driving their adoption among individuals attempting to quit smoking. The growing awareness of the health risks associated with smoking and the increasing number of anti-smoking initiatives globally are further fueling the demand for effective smoking cessation solutions. As new formulations are developed to enhance the efficacy of nicotine delivery, the market for buccal drug delivery systems in this application area is poised for significant growth.

Motion Sickness:

Buccal drug delivery systems are also being utilized for the treatment of motion sickness, particularly through the application of medications such as scopolamine. These systems provide rapid relief from symptoms by allowing the active ingredient to be absorbed directly through the buccal mucosa, offering a convenient alternative to traditional oral medications. The effectiveness of buccal delivery is particularly valuable for patients who experience nausea and vomiting during travel, as it allows for quick intervention without the need for water or swallowing pills. The increasing prevalence of travel-related motion sickness, along with the rising demand for non-invasive treatments, is expected to drive the growth of buccal systems in this application segment.

By Distribution Channel

Hospitals:

Hospitals represent a significant distribution channel for buccal drug delivery systems, as healthcare providers increasingly recognize the advantages of these formulations for patient care. The ability to administer medications quickly and effectively in hospital settings is crucial, especially in emergency situations where time is of the essence. Additionally, hospitals often receive bulk supplies of specialized medications, including buccal formulations, ensuring their availability for patients in need. The growing trend towards personalized medicine and tailored treatments within hospitals is further driving the demand for buccal drug delivery systems. As hospitals continue to embrace innovative healthcare solutions, the market for buccal products within this channel is expected to expand.

Retail Pharmacies:

Retail pharmacies serve as a major distribution channel for buccal drug delivery systems, offering consumers access to a wide range of over-the-counter and prescription products. The convenience of purchasing medications directly from pharmacies enables patients to easily obtain buccal formulations for various applications, including pain relief and hormone replacement. Retail pharmacies often stock popular buccal products such as lozenges and films, catering to the growing demand for non-invasive drug delivery methods. As more consumers become aware of the benefits of buccal delivery, retail pharmacies are likely to expand their offerings of these products, further driving market growth. The increasing emphasis on self-care and accessible healthcare solutions is also expected to benefit this distribution channel.

Online Pharmacies:

The rise of online pharmacies has revolutionized the distribution of buccal drug delivery systems, providing consumers with greater convenience and access to a wider selection of products. Online platforms allow patients to order medications from the comfort of their homes, eliminating barriers such as transportation and accessibility. The growing trend of e-commerce in the pharmaceutical sector is expected to continue driving the demand for buccal formulations, particularly as more consumers seek non-invasive and convenient treatment options. Additionally, the ability to compare prices and find specialized products online enhances the overall shopping experience for patients. As online pharmacies continue to gain popularity, they are likely to play an increasingly important role in the distribution of buccal drug delivery systems.

By Ingredient Type

Lidocaine:

Lidocaine is a widely used ingredient in buccal drug delivery systems, primarily due to its effectiveness as a local anesthetic. Its rapid absorption through the buccal mucosa allows for quick pain relief, making it a popular choice for dental procedures and treatment of oral lesions. The ability of lidocaine to provide immediate relief without the need for injections enhances patient comfort and compliance. Furthermore, ongoing research into novel formulations of lidocaine for buccal delivery is expected to expand its applications beyond traditional uses, potentially addressing new therapeutic areas. As the demand for effective pain management solutions continues to rise, the market for lidocaine-based buccal products is expected to grow significantly.

Testosterone:

Testosterone is becoming an increasingly important ingredient in buccal drug delivery systems, particularly for hormone replacement therapy in males experiencing low testosterone levels. The buccal route of administration offers a convenient and effective means of delivering testosterone directly into the bloodstream, improving bioavailability and providing consistent therapeutic effects. The growing awareness of men's health issues and the increasing emphasis on hormone replacement therapies are driving the demand for buccal formulations containing testosterone. As advancements in formulation technology continue to improve the efficacy and patient acceptance of these products, the market for testosterone-based buccal drugs is expected to expand.

Nicotine:

Nicotine is a key ingredient in buccal drug delivery systems designed for smoking cessation. Products such as nicotine lozenges and buccal patches provide an effective means of delivering nicotine to help reduce cravings and withdrawal symptoms in individuals attempting to quit smoking. The convenience and ease of use of these formulations make them appealing to a wide range of patients. As the global focus on smoking cessation efforts intensifies, the market for nicotine-containing buccal products is projected to grow significantly. Additionally, ongoing research into the development of new nicotine delivery systems is expected to enhance their effectiveness and optimize the smoking cessation process.

Scopolamine:

Scopolamine is another vital ingredient in buccal drug delivery systems, particularly for the prevention of motion sickness and postoperative nausea. The rapid absorption of scopolamine through the buccal mucosa allows for effective and timely relief from symptoms associated with motion sickness. The growing prevalence of travel and the increasing use of scopolamine for various therapeutic applications are driving the demand for buccal formulations containing this ingredient. Furthermore, ongoing research aimed at improving the pharmacokinetic profile of scopolamine-based products is expected to enhance their effectiveness and patient acceptance. As consumers seek convenient and effective treatment options for motion sickness, the market for scopolamine in buccal drug delivery systems is anticipated to experience significant growth.

By Region

The Buccal Drug Delivery Systems market exhibits a diverse regional landscape, with North America leading the market share due to the presence of a well-established pharmaceutical industry and increased investment in research and development. The North American market is expected to grow at a CAGR of around 11.0%, driven by rising chronic disease prevalence, a growing aging population, and increasing consumer awareness regarding innovative drug delivery methods. The favorable regulatory environment and strong distribution networks further position the region as a key player in the global buccal drug delivery market. Coupled with the increasing adoption of advanced healthcare solutions, North America is set to maintain its dominance throughout the forecast period.

Europe is also witnessing considerable growth in the buccal drug delivery systems market, spurred by the rising healthcare expenditure and increasing focus on patient-centric drug formulations. The European market benefits from a strong emphasis on research and innovation within the pharmaceutical sector, leading to the development of novel buccal drug delivery systems tailored for specific therapeutic applications. Furthermore, the increasing awareness of the benefits of buccal administration, coupled with the growing acceptance of personalized medicine, is expected to drive growth in this region. The Asia Pacific region is anticipated to experience rapid growth as well, owing to the expanding healthcare infrastructure and rising disposable incomes, making effective healthcare solutions more accessible to the population.

Opportunities

The Buccal Drug Delivery Systems market is poised for significant opportunities, particularly in the development of innovative formulations that cater to an expanding range of applications. As research and development efforts continue to progress, there is a growing potential for new drugs to be formulated for buccal delivery, addressing various therapeutic areas such as pain management, hormone replacement, and smoking cessation. The trend towards personalized medicine further enhances these opportunities, allowing for the creation of tailored buccal drug delivery systems that meet individual patient needs. With ongoing advancements in technology and formulation methodologies, companies could capitalize on these opportunities to introduce novel products that enhance patient compliance and improve therapeutic outcomes.

Another notable opportunity lies in the increasing demand for non-invasive drug delivery methods among consumers and healthcare providers. As patients seek alternative solutions to traditional oral or injectable medications, buccal drug delivery systems offer a convenient and effective option. The market for buccal formulations can be expanded by targeting specific demographics, such as the elderly, who may have difficulty swallowing pills, or children who may resist conventional medication methods. Additionally, the rise in e-commerce and online pharmacies presents an opportunity for manufacturers to reach a broader consumer base and enhance the accessibility of buccal drug delivery systems. As the trend towards self-care and at-home treatment continues to grow, the buccal drug delivery market stands to benefit significantly.

Threats

Despite the promising growth prospects for the Buccal Drug Delivery Systems market, several threats could impede its progress. One of the primary challenges is the regulatory landscape, which can vary significantly across different regions. Navigating the complexities of regulatory approvals and compliance can be time-consuming and costly for manufacturers, potentially delaying the introduction of new products to the market. Additionally, any changes in regulations or increased scrutiny on the safety and efficacy of drug delivery systems could hinder market growth. Moreover, the presence of established competitors and traditional drug delivery routes may pose a threat, as they can create barriers to entry for new players in the market.

Another significant threat to the Buccal Drug Delivery Systems market is the potential for adverse effects or complications associated with certain formulations. For instance, allergic reactions or irritation at the application site may deter patients from using buccal products. Manufacturers must prioritize patient safety and invest in rigorous testing and quality control measures to ensure the reliability of their products. Furthermore, fluctuating raw material prices and supply chain disruptions may impact production costs and product availability. As the market continues to evolve, addressing these threats will be crucial for sustaining growth and maintaining consumer trust.

Competitor Outlook

• Eli Lilly and Company
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• AbbVie Inc.
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Mylan N.V.
• Sanofi S.A.
• Valeant Pharmaceuticals International, Inc.
• Sun Pharmaceutical Industries Ltd.
• Reddy's Laboratories Ltd.
• Indivior PLC
• Ferring Pharmaceuticals

The competitive landscape of the Buccal Drug Delivery Systems market is characterized by the presence of several prominent players, each striving to innovate and capture market share. The leading companies are focusing on research and development activities to create advanced formulations that offer enhanced efficacy, safety, and patient compliance. As the demand for buccal drug delivery systems grows, these companies are investing in new technologies and partnerships to bring novel products to market. Furthermore, the competitive nature of this market is driving companies to enhance their marketing strategies and improve distribution channels to ensure wider accessibility of their products.

Among the major players, Eli Lilly and Company is recognized for its commitment to developing innovative healthcare solutions, including products that leverage buccal drug delivery systems for managing various medical conditions. Their research initiatives focus on enhancing drug formulation technologies and optimizing delivery mechanisms to improve patient outcomes. Another key player, Pfizer Inc., has a robust portfolio of buccal formulations and is actively involved in exploring new therapeutic areas and applications for buccal drug delivery systems. The company's ongoing commitment to research and development positions them well to capitalize on emerging trends within the market.

GlaxoSmithKline plc is also a notable competitor, leveraging its extensive expertise in pharmaceuticals to develop effective buccal drug delivery products. With a strong focus on patient-centric solutions, they are dedicated to addressing the evolving needs of consumers and healthcare professionals. Additionally, Sanofi S.A. has made significant advancements in buccal drug delivery formulations, particularly in hormone replacement therapies and pain management products. Their ongoing research and innovation initiatives underscore their position as a key player in the buccal drug delivery market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Mylan N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AstraZeneca
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Indivior PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Ferring Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Reddy's Laboratories Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sun Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Buccal Drug Delivery Systems Market, By Application
    • 6.1.1 Pain Management
    • 6.1.2 Hormone Replacement
    • 6.1.3 Smoking Cessation
    • 6.1.4 Motion Sickness
    • 6.1.5 Others
  • 6.2 Buccal Drug Delivery Systems Market, By Product Type
    • 6.2.1 Mucoadhesive Tablets
    • 6.2.2 Buccal Patches
    • 6.2.3 Lozenges
    • 6.2.4 Gels
    • 6.2.5 Films
  • 6.3 Buccal Drug Delivery Systems Market, By Ingredient Type
    • 6.3.1 Lidocaine
    • 6.3.2 Testosterone
    • 6.3.3 Nicotine
    • 6.3.4 Scopolamine
    • 6.3.5 Others
  • 6.4 Buccal Drug Delivery Systems Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Buccal Drug Delivery Systems Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Buccal Drug Delivery Systems market is categorized based on

By Product Type

• Mucoadhesive Tablets
• Buccal Patches
• Lozenges
• Gels
• Films

By Application

• Pain Management
• Hormone Replacement
• Smoking Cessation
• Motion Sickness
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Lidocaine
• Testosterone
• Nicotine
• Scopolamine
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Eli Lilly and Company
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• AbbVie Inc.
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Mylan N.V.
• Sanofi S.A.
• Valeant Pharmaceuticals International, Inc.
• Sun Pharmaceutical Industries Ltd.
• Reddy's Laboratories Ltd.
• Indivior PLC
• Ferring Pharmaceuticals